Results 1 to 10 of about 126,219 (197)
Enhanced efficacy of 0.05% cyclosporine a combined with absorbable punctal plugs in Sjögren’s syndrome-associated dry eye: a paired-eye clinical trial [PDF]
Frontiers in MedicineIntroductionTo compare the efficacy of combination therapy using 0.05% cyclosporine A (CsA) and absorbable punctal plugs with that of CsA monotherapy in patients with Sjögren’s syndrome-associated dry eye (SS-DE) using a paired-eye randomized controlled ...
Yi Dong +6 more
doaj +2 more sources
Treatment of thrombotic thrombocytopenic purpura
Терапевтический архив, 2021 The review discusses approaches to treatment of acquired thrombotic thrombocytopenic purpuгa (aTTP). In patients with aTTP plasma exchanges, glucocorticosteroids allow to stop an acute attack of TTP, and use of rituximab allows to achieve remission.
Gennadii M. Galstyan +3 more
doaj +1 more source
Treatment of ocular rosacea:comparative study of topical cyclosporine and oral doxycycline [PDF]
International Journal of Ophthalmology, 2015 AIM:To compare the effectiveness of topical cyclosporine A emulsion with that of oral doxycycline for rosacea associated ocular changes and dry eye complaints.METHODS:One hundred and ten patients with rosacea were screened.
Aysegul Arman +2 more
doaj +1 more source
Clinics in Dermatology, 1989 Cyclosporine A (CsA) is a neutral lipophilic compound that was first isolated in the 1970s from the fungal species Tolypocladium inflatum gams. CsA is a cyclic polypeptide that consists of 11 amino acids and that has a molecular weight of 1202 daltons.1 It was found to have potent immunosuppressive properties and was initially used in the late 1970s to
Gupta, Aditya K. +7 more
openaire +3 more sources
Problems in pharmaceutical compounding of eye-drops with cyclosporine A [PDF]
Farmacja Polska, 2019 Cyclosporine A is very effective in treatment of many ophthalmic pathologies like immunological and inflammatory diseases of the cornea, conjunctive or uvea. It is also used to prevent corneal graft rejection and to treat dry eye syndrome.
Eliza Katarzyna Wolska +2 more
doaj +1 more source
Application of cyclosporine A in the treatment of chronic spontaneous urticaria
Pifu-xingbing zhenliaoxue zazhi, 2022 Cyclosporine A (CsA), an immune-suppressive agent, is effective in the treatment of chronic spontaneous urticaria (CSU). It is recommended as the three-line treatment for chronic urticaria and for patients with severe disease refractory to antihistamine ...
Shanshan OU +6 more
doaj +1 more source
Comparison of topical application of cyclosporine A to prednisolone in treatment of dry eye disease
Delta Journal of Ophthalmology, 2023 Background Dry eye disease (DED) is a common ophthalmic disorder which affects 5–50% of the global population. Aim The aim of this study was to compare the effects of topical application of cyclosporine A (CsA) to prednisolone in patients with DED ...
Marwa A Zaky +3 more
doaj +1 more source
Journal of Transplantation, 2012 The discovery and use of cyclosporine since its inception into clinical use in the late 1970s has played a major role in the advancement of transplant medicine. While it has improved rates of acute rejection and early graft survival, data on long-term survival of renal allografts is less convincing.
Dustin Tedesco, Lukas Haragsim
openaire +3 more sources
Frontiers in Pharmacology, 2021 Due to the widely application of Cyclosporine A (CsA) as an immunosuppressant in clinic, it is necessary to study its potential toxicity. Therefore, we used zebrafish as a model animal to evaluate the toxicity of CsA on embryonic development. Exposure of
Mengqi Wan +11 more
doaj +1 more source
Pharmaceutics, 2020 The physiological protective mechanisms of the eye reduce the bioavailability of topically administered drugs above all for those with high molecular weight and /or lipophilic characteristics, such as Cyclosporine A (CyA).
Eleonora Terreni +6 more
doaj +1 more source